| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.963 | 14.260 | 18.591 | 17.720 | 20.277 | 20.951 | 24.827 | 26.034 | 22.390 | 17.183 |
| Total Income - EUR | 17.963 | 14.260 | 18.591 | 17.720 | 20.277 | 20.951 | 28.870 | 26.034 | 22.390 | 17.183 |
| Total Expenses - EUR | 8.210 | 11.034 | 8.331 | 8.441 | 10.094 | 12.335 | 31.149 | 8.063 | 10.815 | 12.282 |
| Gross Profit/Loss - EUR | 9.753 | 3.226 | 10.260 | 9.279 | 10.183 | 8.616 | -2.279 | 17.971 | 11.575 | 4.901 |
| Net Profit/Loss - EUR | 9.223 | 2.726 | 9.276 | 8.747 | 9.575 | 8.026 | -3.145 | 17.190 | 10.001 | 4.051 |
| Employees | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Neuroclinic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 34.738 | 34.384 | 33.802 | 33.182 | 32.539 | 25.774 | 1.152 | 1.156 | 1.153 | 1.146 |
| Current Assets | 11.631 | 533 | 3.202 | 3.034 | 5.299 | 3.765 | 19.872 | 20.944 | 24.110 | 27.412 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 10.301 | 136 | 102 | 1.175 | 909 | 830 | 689 | 10.664 | 399 | 0 |
| Cash | 1.330 | 397 | 3.101 | 1.859 | 4.390 | 2.935 | 19.184 | 10.280 | 23.711 | 27.412 |
| Shareholders Funds | 23.507 | 2.835 | 12.063 | 20.589 | 29.355 | 17.598 | 14.063 | 17.710 | 17.954 | 21.905 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 22.862 | 32.081 | 24.941 | 15.627 | 8.482 | 11.940 | 6.962 | 4.389 | 7.309 | 6.653 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuroclinic Srl